Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6

Denise A. Yardley, Adam Brufsky, Robert E. Coleman, Pierfranco F. Conte, Javier Cortes, Stefan Glück, Jean Mark A Nabholtz, Joyce O'Shaughnessy, Robert M. Beck, Amy Ko, Markus F. Renschler, Debora Barton, Nadia Harbeck

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6'. Together they form a unique fingerprint.